by Hansraj Agrawal | Mar 21, 2026 | Share Market
Last Updated : Mar 21 2026 | 5:50 PM IST
Dr. Reddy’s Laboratories announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to advanced GLP-1 receptor agonistbased therapy for the management of type 2 diabetes in India.
Dr. Reddy’s has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company’s Day-1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:31 AM IST
Source link
by Hansraj Agrawal | Mar 21, 2026 | Share Market
Last Updated : Mar 21 2026 | 10:31 AM IST
At board meeting held on 20 March 2026
The board of Fractal Analytics at its meeting held on 20 March 2026 has approved the investment of USD 0.3 crore, by Fractal Analytics Inc. (Fractal US), wholly owned material subsidiary of the Company, in Asper.Ai Inc. (Asper US), step down subsidiary of the Company.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:31 AM IST
Source link
by Hansraj Agrawal | Mar 21, 2026 | Share Market
Last Updated : Mar 21 2026 | 10:16 AM IST
At meeting held on 20 March 2026
The board of Fractal Analytics at its meeting held 20 March 2026 has approved an increase in the investment limit in Fractal US, a
wholly owned material subsidiary of the Company, by an INR equivalent of USD 4.5 crore, to invest the funds in one or more tranches, such that all investments by the Company in Fractal US including all previous investments shall not exceed INR equivalent of USD 15 crore.
Out of the proposed investment of USD 4.5 crore, INR 262.3 crore (approx. USD 2.8 crore) will be utilized for repayment of loans availed by Fractal US, which forms part of the use of proceeds towards one of the
objects of the Offer (IPO), and the balance will be utilized strategically for working capital requirements and strengthening the capital base of Fractal US.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:16 AM IST
Source link
by Hansraj Agrawal | Mar 21, 2026 | Share Market
Last Updated : Mar 21 2026 | 10:16 AM IST
At meeting held on 20 March 2026
The board of Fractal Analytics at its meeting held 20 March 2026 has approved the investment of Rs 39.4 crore in one or more tranches by way of subscription in equity shares of Analytics Vidhya Educon (AVEPL), a wholly owned subsidiary of the Company.
AVEPL was incorporated on 18 February 2014. It is engaged in the business of providing a web platform service to impart knowledge related to analytics through paper and web articles, competitions, community events, and also includes corporate training, placement, and job
provider services.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:16 AM IST
Source link
by Hansraj Agrawal | Mar 21, 2026 | Share Market
Last Updated : Mar 21 2026 | 10:16 AM IST
At meeting held on 20 March 2026
The board of Fractal Analytics at its meeting held 20 March 2026 has approved the sale and transfer of the business units namely EdTech, Fractal Analytics Academy (FAA) and Iqigai.ai together with their respective employees, contracts, consultants, intellectual property rights, licenses and such other assets and liabilities as may be identified by the Company and attributable to the said business units, to Analytics Vidhya Educon (AVEPL), a wholly owned subsidiary of the Company, as a whole and on a going concern basis, by way of a slump sale, for an aggregate consideration of Rs 10.9 crore.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:04 AM IST
Source link
by Hansraj Agrawal | Mar 21, 2026 | Share Market
Last Updated : Mar 21 2026 | 5:50 PM IST
Zydus Lifesciences has launched Semaglutide Injection under the brand names SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.
Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, Zydus offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost. Zydus’ Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of the treatment will be approximately Rs. 2,200.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:04 AM IST
Source link
